Publications by authors named "Fumiyasu Igata"

Article Synopsis
  • A 53-year-old man who works as a hairdresser has serious asthma problems caused by a condition called EGPA, which affects multiple body systems.
  • He tried a treatment called mepolizumab but didn't get better, so he switched to a new medicine called tezepelumab.
  • After starting tezepelumab, he felt much better, needed less other medication, and his lung function improved, suggesting it could be a good option for others with similar asthma issues.
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on the effectiveness and safety of two treatments for extensive-stage small-cell lung cancer (ES-SCLC): atezolizumab combined with chemotherapy versus durvalumab combined with chemotherapy.
  • A total of 40 patients were analyzed, finding no significant differences in survival rates or response rates between those receiving atezolizumab (5.6 months progression-free survival) and durvalumab (5.4 months) during treatment.
  • The study concludes that both treatment regimens are effective and have a similar safety profile in real-world settings, aligning with previous clinical trial outcomes for Japanese ES-SCLC patients.
View Article and Find Full Text PDF

Background/aim: Nivolumab and ipilimumab combination therapy has been extensively explored for the treatment of advanced non-small-cell lung cancer (NSCLC) through the pivotal phase III trials CheckMate 227 and CheckMate 9LA. However, the relationship between immune-related adverse events (irAEs) and the effectiveness of nivolumab plus ipilimumab-based therapy in a real-world clinical setting remains uncertain.

Patients And Methods: We performed a retrospective analysis of 28 patients with advanced or recurrent NSCLC who underwent treatment with nivolumab plus ipilimumab, with or without platinum-doublet chemotherapy, from February 2021 to January 2023.

View Article and Find Full Text PDF

Background: In interstitial pneumonia (IP)-associated lung cancer, immune checkpoint inhibitor pneumonitis (ICIP) is common with immune checkpoint inhibitor (ICI) treatment. The purpose of the present study was to clarify the safety and efficacy of ICI treatment for patients with lung cancer with IP.

Methods: This multicentre retrospective observational study was conducted from June 2016 to December 2020 in patients with primary lung cancer with IP who received ICI treatment.

View Article and Find Full Text PDF
Article Synopsis
  • Platinum-doublet chemotherapy combined with PD-1/PD-L1 inhibitors improves survival in advanced non-small cell lung cancer (NSCLC), with the IMpower150 study showing positive outcomes for ABCP therapy (atezolizumab, bevacizumab, paclitaxel, and carboplatin).
  • A retrospective analysis of 30 Japanese NSCLC patients revealed a median age of 69, primarily male (80%), and high objective response rates (73.9%) with median progression-free survival of 8.3 months.
  • The safety profile was promising, with only one case (3.3%) of ICI-induced pneumonitis, indicating ABCP therapy is effective and safe in this population, similar to findings
View Article and Find Full Text PDF

Background: Pemetrexed is a key drug in chemotherapy for nonsquamous non-small-cell lung cancer (nonsq NSCLC). Several studies have reported thyroid transcription factor-1 (TTF-1) as a biomarker of the efficacy in chemotherapy regimens, including pemetrexed in non-Asian people.

Objective: We aimed to examine the impact of the results of the TTF-1 immunostaining of tumor cells on the therapeutic effect of chemotherapy in Japanese patients with nonsq NSCLC.

View Article and Find Full Text PDF

Afatinib is a second-generation, oral, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). One of the most common adverse effects of affatinib is diarrhea, which may lead to acute kidney injury (AKI) due to severe plasma volume loss; however, no case of glomerular injury directly induced by afatinib has been reported to date. Here, we describe the case of a 53-year-old Japanese male patient with advanced lung adenocarcinoma who twice developed AKI requiring dialysis, once after starting and once after increasing the dose of afatinib.

View Article and Find Full Text PDF

A 72-year-old man, diagnosed with advanced lung squamous cell carcinoma, was administered of cisplatin plus gemcitabine with necitumumab, a human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), as a sixth-line treatment. Tumor shrinkage was observed, but asymptomatic grade 4 hypomagnesemia occurred on day 8 of the second cycle. He received magnesium replenishment and hypomagnesemia recovered on day 40, but tumor progression was observed during the period of magnesium correction.

View Article and Find Full Text PDF

Background: Transbronchial lung cryobiopsy (TBLC) is a new technique that enables larger tissue collection than can be obtained by conventional transbronchial lung biopsy. TBLC is becoming popular worldwide and is performed for diffuse lung disease and lung cancer. However, only a few reports of TBLC have been published in Japan.

View Article and Find Full Text PDF

Background A global multicenter study demonstrated superiority of carboplatin + nab-paclitaxel (PTX) therapy compared to carboplatin + PTX in terms of response rate (RR) and non-inferiority in terms of progression free survival (PFS) and overall survival (OS) in untreated patients with stage IIIB/IV non-small cell lung cancer; no clinical findings have so far been reported on maintenance therapies with nab-PTX. The aim of this study was to determine the efficacy and safety of maintenance therapy with nab-PTX following carboplatin + nab-PTX combination therapy. Methods Carboplatin (AUC 6) was administered on Day 1; and nab-PTX 100 mg/m on Days 1, 8, and 15, and dosing was repeated in 4 courses of 4 weeks each.

View Article and Find Full Text PDF

The proportion of lung cancer patients under 50 years old is small at approximately 510%, but as with patients older than 50, the number is on the rise. Although lung cancer treatment strategies have undergone extensive transformation in recent years based on the presence or absence of oncogenic driver mutations, there are few reports regarding these mutations in the young or the relationship between clinical setting and prognosis. Therefore, we conducted a study of clinical features in 36 patients under the age of 50 who were diagnosed with primary lung cancer from October 2008 to November 2015.

View Article and Find Full Text PDF

A 66-year-old woman, who had been treated with systemic corticosteroids for four months for vasculitis of unknown etiology, was referred to our department due to a fever, dyspnea and patchy ground-glass opacities on chest computed tomography. As transbronchial biopsy specimens were suggestive of interstitial pneumonia, the prescribed dose of corticosteroids was increased. However, the patient developed pyrexia and presented diffuse ground-glass attenuation in the lungs bilaterally.

View Article and Find Full Text PDF

A 22-year-old man was admitted following the detection of right hilar enlargement during a medical checkup. The patient's serum angiotensin-converting enzyme (ACE) level was abnormally high, and a needle aspiration biopsy showed non-caseating epithelioid cell granulomas. Surgical resection was performed, and the resected specimens showed irregularly shaped seminoma nests with intervening stroma consisting of epithelioid cell granulomas.

View Article and Find Full Text PDF